Compare RENX & XRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RENX | XRTX |
|---|---|---|
| Founded | 2021 | 2011 |
| Country | United States | Canada |
| Employees | 38 | N/A |
| Industry | | Pharmaceuticals and Biotechnology |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2M | 3.9M |
| IPO Year | 2023 | 2018 |
| Metric | RENX | XRTX |
|---|---|---|
| Price | $1.06 | $1.04 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 122.6K | ★ 358.6K |
| Earning Date | 11-13-2026 | 11-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $8,220,449.00 | N/A |
| Revenue This Year | $109.28 | N/A |
| Revenue Next Year | $53.56 | $392.31 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 3860.67 | N/A |
| 52 Week Low | $1.15 | $0.35 |
| 52 Week High | $203.14 | $3.60 |
| Indicator | RENX | XRTX |
|---|---|---|
| Relative Strength Index (RSI) | 25.38 | 37.23 |
| Support Level | N/A | $0.37 |
| Resistance Level | $2.12 | $2.26 |
| Average True Range (ATR) | 0.19 | 0.23 |
| MACD | -0.07 | -0.04 |
| Stochastic Oscillator | 8.22 | 21.03 |
RenX Enterprises Corp is engaged in real property development using purpose-built, prefabricated modules constructed from both wood and steel. The Company's operations mainly focused on the acquisition, entitlement, and development of residential properties in high-growth markets across the United States. These efforts included the direct acquisition of land, strategic investments in real estate entities, and joint venture partnerships targeting green, single-family, and multifamily housing projects. The company operates in four segments: real estate development, technology, compost sales, and logistics. The company generates from the compost sales.
XORTX Therapeutics Inc is a clinical-stage pharmaceutical company focused on developing therapies to treat gout and progressive kidney disease modulated by aberrant purine and uric acid metabolism in orphan disease indications such as allopurinol-intolerant gout and autosomal dominant polycystic kidney disease, as well as more prevalent type 2 diabetic nephropathy and fatty liver disease. Its focus is on developing products to slow and/or reverse the progression of these diseases. The Company operates in one reportable operating segment: the development and commercialization of therapies to treat hyperuricemia-related diseases.